Molecular studies revealed that infiltrating macrophages secrete inflammatory cytokines and blocking IL1β reduced the pro-tumoral effect of these cells in preclinical models of RCC (21); more recently, a multidimensional analysis suggested that immunotherapy combined with inhibition of IL1β promoted tumor regression and remodeled the immune infiltration in mice (27). Here, IL1B is linked to neoplasm.